Sam Battenberg, BS

Peggy Modaff, MS, CGC

Once Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial

  • Describe the molecular basis of achondroplasia and the mechanism of action of navepegritide as a targeted therapy. 
  • Summarize the design and outcomes of the APPROACH randomized clinical trial, including the primary endpoint and selected secondary clinical measures. 
  • Discuss psychosocial considerations related to growth-promoting treatments in children with achondroplasia. 
Session date: 
02/11/2026 - 4:00pm to 5:00pm CST
Location: 
Virtually
WI 53705
United States
See map: Google Maps
  • 1.00 AAPA Category 1 CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 CDR CPEUs
  • 1.00 NSGC Category 1 CEU Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™
Add to calendar: 
Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Sam Battenberg, BS (grad student)
Peggy Modaff, MS, CGC